

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



UMP HEALTHCARE HOLDINGS LIMITED

聯合醫務集團有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock code: 722)

PROFIT WARNING

This announcement is made by UMP Healthcare Holdings Limited (the “**Company**” and together with its subsidiaries, the “**Group**”) pursuant to Rule 13.09 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) and the Inside Information Provisions (as defined in the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571, Laws of Hong Kong).

The board of directors (the “**Board**”) of the Company wishes to inform the shareholders of the Company and potential investors that, based on the information currently available to the Board and the preliminary review of the unaudited management accounts of the Group, the Board expects that the net profit of the Company for the financial year ended 30 June 2016 will represent a significant decrease by approximately 75% as compared with the corresponding period in 2015. Such decrease is mainly attributable to the recognition of expenses incurred in connection with the listing of the Company on The Stock Exchange of Hong Kong Limited, the equity-settled share-based payment expenses and the incremental expenses relating to the development of the PRC Corporate Healthcare Solution and Clinical Healthcare Business (as defined in the Company’s interim report for the six months ended 31 December 2015 (the “**Interim Report**”), as mentioned in the prospectus of the Company dated 17 November 2015 (the “**Prospectus**”). Please refer to “Risk factors — Risks relating to the Group’s business and industry — The Group’s historical results of operations and financial performance are not indicative of future performance, and the Group may not be able to achieve or sustain the historical level of growth for revenue and profitability” in the Prospectus.

The additional expenses stated above primarily include (i) non-recurring listing related expenses of approximately HK\$16.4 million (as opposed to the estimated amount of HK\$15.4 million as disclosed in the Prospectus); (ii) equity-settled share-based payment expenses of approximately HK\$7.6 million; (iii) the booking of pre-opening expenses for a clinic in Shanghai of approximately HK\$7.5 million, which mainly represent rent paid during the period of such clinic’s licence application, renovation and staff costs; and (iv) the booking of pre-opening expenses for clinics in Beijing of approximately HK\$7.5 million,

which is recognised by the Company as a share of loss of a joint venture. Similar to the expenses incurred for the new clinic in Shanghai, such pre-opening expenses mainly represent rent paid during the period of the Beijing clinics' licences application, renovation and staff costs.

The Company's (i) Hong Kong & Macau Corporate Healthcare Solution Services, (ii) Hong Kong & Macau Clinical Healthcare Services and (iii) PRC Health Check-up Business (each as defined in the Interim Report) for the financial year ended 30 June 2016 have continued to perform well and are in line with historical performances. Based on the preliminary review of the unaudited management accounts of the Group, the Company expects to record a total revenue of approximately HK\$452 million, representing a year on year increase of approximately 12.9%. The total number of patient visits also increased from approximately 1.29 million in FY2015 to approximately 1.41 million in FY2016. The Company will provide additional breakdown of financial and operational information in its full year results announcement.

The Company has yet to finalise the annual results of the Group for the financial year ended 30 June 2016. The information contained in this announcement is only based on the preliminary review of the Company's management accounts with reference to the information currently available to the Board and is not based on any figures or information that has been audited or reviewed by the auditors or the audit committee of the Company. Shareholders and investors are advised to read carefully the results announcement of the Company for the year ended 30 June 2016, which is expected to be published before the end of September 2016.

Shareholders and potential investors should exercise caution when dealing in the shares of the Company.

By Order of the Board
UMP Healthcare Holdings Limited
Sun Yiu Kwong
Chairman and Chief Executive

Hong Kong, 17 August 2016

As at the date of this announcement, the Board comprises Dr. SUN Yiu Kwong as Chairman, Chief Executive and executive director, Ms. KWOK Cheuk Kwan, Jacquen, as managing director and executive director, Mr. TSANG On Yip, Patrick, Dr. SUN Man Kin, Michael, Mr. LEE Kar Chung, Felix and Mr. JIANG Tianfan as executive directors, and Mr. LEE Luen Wai, John BBS JP, Dr. LI Kwok Tung, Donald SBS JP and Mr. YEUNG Wing Sun, Mike as independent non-executive directors.